

Contents

1 Introduction.....	1
Definitions.....	1
Historical Development of Neuroprotection.....	1
Intrinsic Neuroprotective Factors.....	3
Neuroprotective Gene Expression	4
Neurotrophic Factors	5
Intrinsic Nonenzymatic Antioxidants	6
Intrinsic Neuroprotective Proteins	6
Stem Cell Factor	9
Role of the Immune System in Neuroprotection	9
Induction of DNA Repair Enzymes for Neuroprotection	10
Pathomechanisms of CNS Injury as Basis for Neuroprotection.....	11
Biomarkers of Neurological Disorders and Neuroprotection	12
CNS Biomarker Identification Using Proteomics.....	12
Brain Imaging for Detection of Biomarkers	13
Role of Neuroprotection in Various Neurological Disorders.....	13
Neuroprotection and Neuroregeneration.....	14
Acute Versus Chronic Neuroprotection	15
Discovery and Evaluation of Neuroprotective Agents.....	15
Neuroprotective Drug Discovery	15
Discovery of CNS Drugs that Penetrate the Blood–Brain Barrier.....	16
In Vitro Assays for the Evaluation of Neuroprotective Agents	17
Oxidative Injury Model to Test Neuroprotective Drugs	18
Apoptosis Model for Designing Neuroprotective Drugs	18
Transgenic Mouse Models of Neurological Disorders	18
Evaluating Effects of Neuroprotective Drugs on Living Brain Slices	19
Role of Brain Imaging in Neuroprotective Drug Discovery and Development	20
Application of Nanotechnology in Neuroprotection.....	22
Evaluation Criteria for Potential Neuroprotective Agents	22
References.....	23

2 Neuroprotective Agents	25
Classification of Neuroprotective Agents	25
Activity-Dependent Neuroprotective Protein	25
Adenosine Analogs	32
Propentofylline.....	32
Antidepressants	33
Antidepressant-Induced Neurogenesis.....	33
Neurogenesis Induced by Electroconvulsive Therapy	33
Neuroprotective Effect of Selective Serotonin Reuptake Inhibitors	34
Antiepileptic Drugs as Neuroprotectives	34
Phenytoin	35
Valproic Acid	36
Levetiracetam.....	36
Anti-inflammatory Agents	37
Aspirin.....	37
Interleukin-1 Antagonists.....	37
COX-2 Inhibitors	38
Gold Microparticles as Anti-neuroinflammatory Agents	39
Minocycline	40
Anti-apoptosis Agents.....	40
Activated Protein C.....	41
Calpain Inhibitors.....	42
Caspase Inhibitors.....	43
DNA-Binding Drugs	43
Lithium.....	43
Olesoxime	44
Omega-3 Fatty Acids	44
Poly(ADP-Ribose) Polymerase Inhibitors	45
Prevention of Apoptosis by Binding of proNGF to Sortilin	46
Antioxidants/Free Radical Scavengers	47
Free Radical Generation	47
Natural Defenses Against Oxidative Stress	47
Effects of Oxidative Damage	48
Measures to Control Oxidative Stress.....	49
Translation of Antioxidant Neuroprotection from Preclinical to Clinical.....	55
Carbon Monoxide and Heme Oxygenase	55
Cell Transplants.....	55
Cells Secreting Neuroprotective Substances.....	56
Stem Cells	57
Stem Cell Activation for Neuroprotection/Regeneration by Glucocorticoids	57
Cytokines.....	57
Erythropoietin	57
Granulocyte Colony-Stimulating Factor	60

Delta-Opioid Receptor Agonists	61
FK960	61
Gene Therapy	62
Glucagon-Like Peptide	63
Glatiramer Acetate	63
Glutamate Antagonists	64
Neuroprotection by Scavenging Blood Glutamate	65
<i>N</i> -Acylethanolamines for Protection Against Glutamatergic Excitotoxicity	66
Glutamate Transporters	66
Glutamate Transporter-Mediated Neuroprotective Effect of Drugs	67
Neuroprotection by Targeting KAI Subunit of Kainate Receptor	67
Glycine-Proline-Glutamate Analogs	68
Herbal Preparations	68
Flavonoid Wogonin	68
Ginseng	69
Hydrogen Sulfide	69
NMDA Receptor Ion Channel Complex	70
NMDA Receptor Antagonists	71
AMPA Receptor Modulators	74
Metabotropic Glutamate Receptor Modulators	74
Cannabinoids	75
Dexanabinol	76
Glutathione	77
Heat Shock Proteins	77
Hormones	78
Estrogen and Neuroprotection	78
Insulin	80
Ion Channel Modulators	81
Calcium Channel Blockers	81
Na ⁺ Channel Blockers	82
Neuroprotective Potassium Channel Inhibitors	83
Kynurenine Inhibitors	83
Leukocyte Adhesion Inhibitors	84
Modafinil	85
Neural Regeneration Protein	85
Neurite Outgrowth-Promoting Prostaglandin Compounds	86
Neuroimmunophilins	86
Cyclosporin-A	87
FK506	87
Rapamycin	88
Neurotrophic Factors	88
Activity-Dependent Neurotrophic Factor	89
Bone Morphogenetic Proteins	89
Brain-Derived Neurotrophic Factor	90
Ciliary Neurotrophic Factor	90

Fibroblast Growth Factors	91
Glial Cell Line-Derived Neurotrophic Factor	92
Insulin-Like Growth Factor.....	92
Nerve Growth Factor.....	93
Neurotrophins	94
Osteogenic Protein-1	94
Pigment Epithelium-Derived Factor	95
Transforming Growth Factor- β 1	95
Vascular Endothelial Growth Factor	95
Neurotrophic Factor-Related Neuroprotective Agents	96
Nicotine and Nicotinic Receptor Agonists	99
Nitric Oxide-Based Neuroprotection	100
Nitric Oxide Synthase Inhibitors	101
Nitric Oxide Mimetics	101
Nootropics.....	102
Piracetam.....	103
Nutraceuticals and Food Constituents	103
Creatine	103
Curcumin/Curry	104
Glyceryltriacetate	106
Green Tea	106
Nicotinamide.....	107
Resveratrol	107
Osmotic Diuretics	108
Mannitol.....	108
Osteopontin.....	109
Oxygen Therapeutics	109
Oxygen Carriers.....	110
Hemoglobin-Based Oxygen Carriers.....	110
Perfluorocarbons as Oxygen Carriers	111
Hyperbaric Oxygen Therapy.....	112
Peptides	112
C3-Derived Peptide for Neuroprotection and Neuroregeneration	113
Corticotropin-Releasing Hormone.....	113
Thyrotropin-Releasing Hormone	113
Vasoactive Intestinal Peptide	114
Pharmacological Preconditioning	115
PPARs as Drug Targets for Neuroprotection	115
Riluzole	116
Role of RNA Interference in Neuroprotection.....	116
Sigma Receptor Agonists as Neuroprotective Agents	117
SIRT Group of Proteins	117
Statins.....	118
Steroids	119
Dehydroepiandrosterone	119

HF0220	120
Sulforaphane	120
Tauroursodeoxycholic Acid	121
Tetanus Toxin as a Neuroprotective Agent	121
Thrombolytic Agents as Neuroprotective Agents.....	122
Uncoupling Protein 2	122
Vaccines as Neuroprotectives.....	123
Vitamins as Neuroprotective Agents.....	123
Vitamin B12	123
Nonpharmacological Approaches to Neuroprotection.....	124
Environmental Enrichment	124
Mental Training.....	125
Physical Exercise	125
Hypothermia	125
Hibernation Induced by Hydrogen Sulfide	127
Ketogenic Diet	128
Nonpharmacological Preconditioning for Neuroprotection.....	128
Transcranial Magnetic Stimulation.....	129
Electrical Fields for Improvement of Cerebral Function in Neurodegeneration	130
Neuroprotective Effect of Exercise.....	131
Hibernation and Neuroprotection	132
Suspended Animation and Neuroprotection	132
References.....	132
3 Neuroprotection in Cerebrovascular Disease	141
Introduction.....	141
Pathophysiology of Cerebral Ischemia	141
Calcium Overload	143
Ion Channel Dysfunction in Stroke.....	143
Role of Oxygen Free Radicals in Cerebral Ischemia.....	143
Role of Nitric Oxide in Cerebral Ischemia	144
Glutamate as a Biomarker of Stroke.....	144
Cerebral Edema in Stroke	144
Gene Expression in Response to Cerebral Ischemia.....	145
Induction of Heat Shock Proteins in Stroke.....	145
Role of Cytokines and Adhesion Molecules in Stroke	146
DNA Damage and Repair in Cerebral Ischemia.....	147
Role of Neurotrophic Factors in Stroke	147
Role of Poly(ADP-Ribose) Polymerase Gene	148
Role of Protease-Activated Receptor 1	149
Reperfusion Injury after Cerebral Ischemia.....	149
Neuroprotection According to Zones in Cerebral Infarction	149
Zone of Ischemic Infarction	150
Penumbra	150

Current Management of Stroke.....	151
Neuroprotection in Stenosis of Intracranial Arteries	152
Neuroprotection in Transient Ischemic Attacks.....	152
Neuroprotective Therapies for Stroke.....	152
Acid-Sensing Ion Channel Blockers	153
AMPA Receptor Antagonists as Neuroprotectives for Stroke	154
Anti-apoptotic Neuroprotectives	154
Antiepileptic Drugs as Neuroprotectives in Stroke.....	156
Anti-HMGB1 Monoclonal Antibody.....	157
Antioxidant Approaches	158
Anti-glutamate Compounds	160
Arimoclomol for Stroke.....	161
Cardiac Glycosides as Neuroprotectives in Stroke	162
Clenbuterol.....	162
Cox-2 Inhibitors for Ischemic Stroke	162
Enoxaparin	163
Estrogen for Stroke	163
Flavones for Neuroprotection in Stroke.....	165
Granulocyte-Macrophage Colony-Stimulating Factor for Cerebral Ischemia.....	166
Modulation of Histamine H ₂ Receptors	166
Inosine for Stroke.....	167
Insulin-Like Growth Factor-I.....	167
Ischemic Preconditioning for Neuroprotection in Stroke	168
Ketone Bodies for Neuroprotection in Stroke.....	169
Mineralocorticoid Receptor Blockade for Neuroprotection	169
Multifunctional Neuroprotective Agents	169
Neuroserpin as a Neuroprotective in Stroke	170
<i>N</i> -2-Mercaptopropionyl Glycine.....	171
NeuroAid.....	171
Neurotrophic Factors as Neuroprotectives for Stroke.....	171
NO-Based Strategies for Neuroprotection in Cerebral Ischemia.....	174
Peroxisome Proliferator-Activated Receptor- γ Agonists	175
PGE2 EP2 Receptor Activation	175
Pioglitazone for Reduction of Stroke Risk in Diabetes	175
Progesterone.....	176
Proteosome Inhibitors	176
Statins for Prevention of and Neuroprotection in Stroke.....	176
Sildenafil	177
Src Receptor Blockade.....	178
Stroke Vaccine	178
SUN-N4057	179
Thrombosis Inhibitors.....	179
Neuroprotectives in Reperfusion Injury.....	180
Prevention of Hemorrhage Following Ischemic Stroke.....	181

Nonpharmacological Neuroprotective Therapies for Stroke	181
Cell Therapy for Stroke.....	186
Neuroprotective Vaccines for Stroke	188
Gene Therapy for Neuroprotection in Cerebrovascular Disease	188
Regulation of microRNAs for Neuroprotection in	
Cerebral Ischemia	192
Neuroprotective Therapies for Cerebral Ischemia: Clinical Trials	192
Failed Clinical Trials of Neuroprotection in Stroke.....	197
Design of Acute Stroke Trial to Facilitate Drug Approval	208
The Ideal Neuroprotective Agent for Stroke.....	208
Future Prospects for Neuroprotection in Stroke	209
References.....	210
4 Neuroprotection in Traumatic Brain Injury	217
Introduction.....	217
Cerebral Hypoxia/Ischemia as a Complication of Trauma.....	217
Traumatic Brain Injury.....	218
Pathophysiology of TBI.....	218
Management of TBI.....	225
Neuroprotection in TBI.....	226
Biological Approaches to Neuroprotection in TBI.....	241
Nonpharmaceutical Approaches to Neuroprotection in TBI	243
Prophylactic Neuroprotection Against TBI	245
Clinical Trials of Neuroprotective Agents in TBI.....	245
Failed Clinical Trials in TBI	247
Concluding Remarks and Future Prospects of	
Neuroprotection in TBI.....	249
References.....	250
5 Neuroprotection in Spinal Cord Injury	255
Introduction.....	255
Pathophysiology of SCI	255
Secondary Mechanisms of SCI.....	256
Neurotrophic Factor Changes in SCI.....	257
Management of SCI	258
Pharmacological Neuroprotective Agents for SCI.....	259
4-Aminopyridine.....	259
Antibodies as Neurite Growth Inhibitors in SCI.....	259
Bacterial Enzyme Chondroitinase ABC	260
Docosahexaenoic Acid as Neuroprotective in SCI	260
Erythropoietin as a Neuroprotective in SCI.....	261
Free Radical Scavengers for Neuroprotection in SCI.....	261
Gacyclidine	262
GYKI 52466.....	262

Immunosuppressants as Neuroprotectants in SCI.....	262
Interleukin-10 for Neuroprotection in SCI	263
Matrix Metalloproteinase Inhibitors for SCI	263
Methylprednisolone	264
Minocycline as Neuroprotective in SCI.....	264
Neurotrophic Factors for Neuroprotection After SCI.....	265
Rho Pathway and Rho Antagonists in SCI	266
Selenium as a Neuroprotective for SCI.....	266
Sialidase for Enhancing Recovery After SCI	267
Targeting the Inflammatory Response for Neuroprotection in SCI.....	267
Uric Acid as Neuroprotective in SCI	268
Nonpharmacological Approaches to SCI.....	268
Hyperbaric Oxygen Therapy.....	268
Hypothermia for SCI.....	268
Cell Therapy for SCI.....	269
Autoimmune T Cells Against CNS Myelin-Associated Peptide	269
Fetal Neural Grafts for SCI.....	269
Olfactory Ensheathing Cells for SCI	269
Oligodendrocyte Precursor Cells for Treatment of SCI.....	270
Schwann Cell Transplants for SCI.....	271
Transplantation of Glial Cells for SCI	271
Stem Cells for SCI	271
Gene Therapy for SCI.....	275
Combined Approaches to SCI	276
Discovery of New Targets for Neuroprotective Therapies in SCI	277
Clinical Trials in SCI	277
References	279
 6 Neuroprotection in Neurodegenerative Disorders	 281
Introduction.....	281
Pathomechanism of Neurodegeneration	281
Dual Role of α -Synuclein in Neuroprotection and Neurodegeneration.....	282
Lack of Neurotrophic Factors	282
Neuroinflammation in Neurodegenerative Disorders	283
Neurodegeneration Associated with Protein Misfolding.....	283
TDP-43 Proteinopathy and Neurodegenerative Diseases	285
Role of Apoptosis in Neurodegenerative Disorders.....	286
Role of Glia in Neurodegeneration	286
Role of Metals in Neurodegeneration	286
Viral Infections and Neurodegeneration	287
Genetic Disorders with Neurodegeneration.....	289
Batten Disease.....	289
Friedreich Ataxia	290

Niemann–Pick Type C Disease.....	291
Creutzfeldt–Jakob Disease.....	292
Approaches to Neuroprotection in Neurodegenerative Disorders	293
Glutamate-Based Therapies for Neurodegenerative Disorders.....	294
Mitochondria Permeability Transition Pore Complex and Neuroprotection	294
References.....	295
7 Neuroprotection in Parkinson’s Disease	297
Introduction.....	297
Pathophysiology of Parkinson’s Disease	297
Oxidative Stress	297
Excitotoxicity.....	299
Asynchronous Neuronal Activity.....	299
Apoptosis	299
Role of Neurotrophic Factors.....	299
Role of Misfolding Proteins.....	300
Genetic Factors in PD	300
Alteration of Dopamine Homeostasis.....	302
Neuroprotective Strategies for PD Based on Pathomechanism	302
RNAi Screening to Identify Neuroprotective Genes in a PD Model	303
Management of Parkinson’s Disease	304
Limitation of Conventionally Administered Dopamine Therapy	305
Treatment of Dementia Associated with PD.....	306
Neuroprotective Therapy in PD	306
Neuroprotective Effect of Currently Used Drugs for PD.....	307
Pramipexole	307
Rasagiline Mesylate	308
Ropinirole	309
Selegiline.....	309
Nonpharmacological Strategies for Neuroprotection in PD	310
Preventive Effect of Exercise and Environmental Enrichment.....	310
Low-Calorie Diet	311
Development of Neuroprotective Therapies for PD	311
Adenosine A _{2A} Receptor Antagonists	311
Anti-apoptotic Strategies for PD.....	312
Calcium Channel Blockers for PD.....	312
Cell Therapies for PD	313
Cogane	315
Creatine and Minocycline	315
Conserved Dopamine Neurotrophic Factor for PD.....	316
Free Radical Scavengers for Neuroprotection in Parkinson’s Disease	316
Gene Therapy for PD.....	318

Heat Shock Protein 70	321
Neuroprotective Effect of DJ-1 Protein	321
Neurotrophic Factors	322
Nrf2-Mediated Neuroprotection in PD	324
Omega-3 Polyunsaturated Fatty Acids	325
RAB3B Overexpression.....	325
RNAi Therapy for PD	326
Safinamide	326
Sirtuin 2 Inhibitors for Neuroprotection in PD	327
Statins and PD.....	328
Targeting Bax	328
Vitamin D for Neuroprotection in PD.....	328
Vaccine for PD	329
Clinical Trials of Neuroprotection in Parkinson's Disease	329
Evaluation of Neuroprotective Therapies for PD.....	330
Current Status and Future Challenges for Neuroprotection in PD	331
References.....	333
8 Neuroprotection in Alzheimer's Disease	337
Introduction.....	337
Pathomechanism of Alzheimer's Disease	337
Role of Glutamate Transport Dysfunction in AD.....	338
Role of Neurotrophic Factors in the Pathomechanism of AD	339
Management of Alzheimer's Disease	339
Neuroprotection in Alzheimer's Disease	339
Inhibition of A β Aggregation	340
Secretase Inhibitors.....	340
AN-1792	342
Monoclonal Antibody m266.....	342
Clioquinol	342
FKBP52 for Neuroprotection from Cu Toxicity in AD.....	343
Phenserine.....	344
Colostrinin.....	345
Inhibition of Neuroinflammation.....	345
Etanercept	345
Neurotrophic Factors/Gene Therapy.....	346
NGF Gene Therapy.....	346
AL-108.....	348
Targeting Plasminogen Activator Inhibitor Type-1 Gene	348
Estrogen and AD.....	348
Antioxidants.....	349
NSAIDS	349
Memantine	349
Dimebon.....	350
Cerebrolysin.....	351

Ginkgo biloba.....	352
Tetrahydrocannabinol for Neuroprotection in AD.....	353
Ladostigil Tartrate.....	354
Phosphodiesterase Inhibitors as Neuroprotectives.....	354
PPAR- γ Agonists.....	354
Role of Statins in Reducing the Risk of AD.....	355
Combined Therapeutic Approaches to AD.....	356
Clinical Trials in AD.....	356
Future Prospects of Neuroprotection in AD.....	356
Mild Cognitive Impairment.....	356
Relation of MCI to AD.....	364
Neuroprotection in MCI.....	365
References.....	365
9 Neuroprotection in Huntington's Disease.....	369
Introduction.....	369
Pathophysiology of HD.....	369
Management of Huntington's disease.....	371
Neuroprotection in Huntington's disease.....	371
Antipsychotic D2 and 5-HT _{1A} Antagonists.....	372
Caspase Inhibitors.....	373
Clioquinol for HD.....	373
Creatine for Stabilizing Bioenergetic Defects.....	373
Cysteamine.....	374
Drugs that Block Inappropriate Calcium Release from Neurons.....	374
Enhancing Protease Activity for Clearance of mHtt.....	375
Eicosapentaenoic Acid.....	375
Free Radical Scavengers.....	375
Histone Deacetylase Inhibitors.....	376
Inhibitors of Polyglutamine Aggregation in HD.....	376
Pridopidine.....	377
Simvastatin as a Neuroprotective in HD.....	377
Single-Chain Fv Antibodies.....	378
SIRT2 Inhibitors for Neuroprotection in HD.....	378
Synaptic Activation of NMDA Receptors.....	379
Tetrabenazine.....	379
Combinatorial Therapy and Targeting Multiple Pathways in HD.....	379
Cell Transplants.....	380
Neurotrophic Factors and Gene Therapy.....	381
RNAi Therapy for Huntington's Disease.....	382
References.....	382
10 Neuroprotection in Amyotrophic Lateral Sclerosis.....	385
Introduction.....	385
Pathophysiology of ALS.....	385

Neuroprotective Therapies for ALS.....	388
Activated Protein C.....	389
AEOL 10150.....	390
AIMSPRO.....	390
Arimoclomol for ALS.....	391
Antisense Therapy.....	391
Creatine for ALS.....	391
Ceftriaxone for ALS.....	392
Coenzyme Q10 for ALS.....	393
COX-2 Inhibitors for ALS.....	393
Dexpramipexole.....	393
Diallyl Trisulfide.....	394
Erythropoietin for ALS.....	394
Gene Therapy for ALS.....	394
Glatiramer Acetate.....	395
Insulin-Like Growth Factor.....	396
Ketogenic Diet for Neuroprotection in ALS.....	396
Lenalidomide.....	397
Lithium for Neuroprotection in ALS.....	398
Methylcobalamin.....	398
Minocycline for ALS.....	399
Olesoxime as a Neuroprotective for ALS.....	399
ONO-2506 for ALS.....	399
Riluzole.....	400
RNAi-Based Therapy for ALS.....	400
Sodium Phenylbutyrate.....	401
Stem Cell Therapy.....	401
Talampanel.....	402
Tamoxifen.....	402
Vaccination for ALS Caused by SOD1 Mutations.....	402
Vascular Endothelial Growth Factor for ALS.....	403
Clinical Trials of Neuroprotective Therapies for ALS.....	403
Concluding Remarks and Future Prospects.....	406
References.....	406
 11 Neuroprotection in Miscellaneous Neurological Disorders.....	 409
Introduction.....	409
Age-Related Dementia.....	409
Enhancing Endogenous Neurotrophic Support of the Aging Brain.....	410
Pharmacological Approaches for Treatment of	
Age-Related Dementia.....	410
Physical Exercise to Prevent Decline of Mental	
Function with Aging.....	412
Vascular Dementia.....	412
Prediction of Dementia in Persons with Vascular Risk Factors.....	413

Management of Subcortical Vascular Dementia.....	413
Dementia with Lewy Bodies.....	414
Neuroprotection in AIDS Dementia	415
Multiple System Atrophy.....	416
Epilepsy.....	416
Mechanisms of Neuronal Damage in Epilepsy.....	417
Strategies for Neuroprotection in Epilepsy.....	418
Control of Seizures and Neuroprotection	418
Cell Therapy for Neuroprotection in Epilepsy.....	420
Gene Therapy for Neuroprotection in Epilepsy.....	422
Spinal and Bulbar Muscular Atrophy	423
Multiple Sclerosis	423
Introduction.....	423
Epidemiology of Multiple Sclerosis	424
Pathophysiology.....	424
Current Management of Multiple Sclerosis.....	425
Specific Therapies for MS Based on Pathomechanism	426
Neuroprotection in Multiple Sclerosis.....	426
Clinical Trials of Neuroprotective Therapies for MS	427
Neuroprotection by Control of Progressive Forms of Multiple Sclerosis	428
Neuroprotection by Controlling Autoimmune Inflammation in the Brain.....	428
Remyelination for Neuroprotection in Multiple Sclerosis.....	430
Agents for Neuroprotection in Multiple Sclerosis	430
Neuroprotection in Transverse Myelitis.....	444
Neuroprotection in Decompression Sickness	445
Neuroprotection in Hydrocephalus	446
Neuroprotection in Normal Pressure Hydrocephalus	446
Neuroprotection in Infections of the CNS	447
Neuroprotection in Bacterial Meningitis	447
Neuroprotective Approach to Rabies	448
Neuroprotection in Cerebral Malaria	449
Neuroprotection in Hypertensive Encephalopathy	449
Neuroprotection in Toxic Encephalopathies	450
Hepatic Encephalopathy	450
Encephalopathy Due to Organophosphorus Poisoning.....	451
Neuroprotection Against Chemotherapy-Induced Brain Damage.....	452
Neuroprotection Against Alcohol.....	453
Neuroprotection in Hypoxia-Ischemia.....	455
Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury.....	455
Neuroprotection in Carbon Monoxide Poisoning	457
Syndrome of Delayed Post-hypoxic Leukoencephalopathy	459
Neuroprotection in Sleep Apnea.....	460
Neuroprotection in Hypoglycemic Coma	461
Neuroprotection in Mitochondrial Dysfunction.....	462

Mitochondrial Permeability Transition	462
Mitochondrial Approaches for Neuroprotection.....	463
Methylene Blue	463
Role of Nanolasers in Evaluation of Mitochondrial Neuroprotectants	465
Neuroprotection in Mitochondrial Encephalopathies	465
Schizophrenia.....	466
Cognitive Impairment in Schizophrenia	466
Neuroprotection in Schizophrenia	466
Neuroprotection in Hearing Loss.....	467
Causes of Hearing Loss	467
Pathomechanism of Hearing Loss	467
Prevention and Treatment of Hearing Loss.....	468
Neuroprotection of Peripheral Nerves	471
Neuroprotective Agents for Peripheral Nerves	471
Neuroprotection in Peripheral Nerve Injuries.....	473
Peripheral Neuropathy	475
Chronic Inflammatory Demyelinating Polyradiculoneuropathy	477
References.....	478
 12 Neuroprotection of the Optic Nerve and the Retina	485
Introduction.....	485
Neuroprotection in Optic Neuropathy	485
Neuroprotection in Optic Neuritis	485
Neuroprotection in Optic Nerve Trauma	487
Potential Regeneration of the Optic Nerve	487
Subthreshold Transpupillary Thermotherapy for Protection of RGCs.....	488
Neuroprotection of Optic Nerve in Glaucoma.....	488
Aminoguanidine as a Neuroprotective in Glaucoma	489
Antiglutamate Agents for Neuroprotection of Optic Nerve.....	490
Betaxolol.....	491
NGF Eye Drops.....	491
Targeting A β in Glaucoma Treatment	492
TNF- α Blockers for Neuroprotection in Glaucoma.....	492
Concluding Remarks About Neuroprotection in Glaucoma.....	492
Neuroprotection in Retinal Ischemia	493
Endogenous Neuroprotection in the Retina	493
β -Adrenoceptor Antagonists.....	494
Brimonidine as a Neuroprotective in Ischemic Retinopathy.....	494
Thioredoxin as a Neuroprotective Agent in Retinal Ischemia.....	495
Erythropoietin for Neuroprotection of Retinal Ischemia	495
Gene therapy for Retinal Neuroprotection.....	496
Hyperbaric Oxygen for Central Retinal Artery Occlusion	496
Protection Against Oxygen-Induced Retinopathy	496

Neuroprotection in Macular Degeneration	497
Epidemiology	497
Pathomechanism of AMD.....	497
Current Treatment of AMD	497
Novel Neuroprotective Strategies Against Retinal Degeneration.....	499
Antiangiogenic Agents.....	499
Protection of Retinal Cells from Oxidative Stress-Induced Apoptosis.....	500
Nutritional Protection Against AMD.....	501
Cell therapy for Macular Degeneration	501
Gene Therapy for Retinal Degeneration	502
RNAi-Based Treatments for AMD	503
Neuroprotection in Proliferative Diabetic Retinopathy	504
Strategies for Neuroprotection in Diabetic Retinopathy.....	504
RNAi-Based Approaches to Diabetic Retinopathy.....	505
Clinical Trials for Optic Nerve and Retinal Neuroprotection.....	505
References.....	507
 13 Neuroprotection During Anesthesia and Surgery.....	 509
Introduction.....	509
Anesthetic Agents as Neuroprotectives	509
Barbiturates	510
Etomidate	511
Propofol.....	512
Ketamine	512
Gaseous Anesthetics	513
Local Anesthetics.....	514
Monitoring of CNS Function During Anesthesia and Surgery.....	514
Monitoring of Cerebral Function	514
Monitoring of Spinal Cord Function During Spinal Surgery	515
Neuroprotection During Cardiovascular Procedures	516
CNS Complications of Cardiac Surgery	516
Neuroprotective Strategies During Cardiac Surgery.....	516
Surgery on the Aorta.....	520
Spinal Cord Protection During Cardiovascular Surgery	521
Cerebral Protection During Organ Transplantation Surgery.....	521
Cerebral Protection During Neurosurgery	521
Cerebral Angiography and Endovascular Surgery.....	522
Cerebral Protection During Surgery for Arteriovenous Malformations.....	522
Cerebral Protection During Surgery of Intracranial Aneurysms	522
Management of Subarachnoid Hemorrhage	523
Cerebral Protection During Carotid Endarterectomy	525
Neuroprotective Measures Prior to Surgery.....	526
Neuroprotection Following Surgery	527
References.....	527

14 Future Prospects of Neuroprotective Therapies	529
Introduction.....	529
Challenges in Neuroprotective Drug Development	529
Promising Areas of Research in Neuroprotection	530
Autoreactive Antibodies	530
Biological Therapies for Neuroprotection	531
Multidisciplinary Approaches to Neuroprotection	531
Index.....	533



<http://www.springer.com/978-1-61779-048-5>

The Handbook of Neuroprotection

Jain, K.K.

2011, XXXI, 547 p., Hardcover

ISBN: 978-1-61779-048-5

A product of Humana Press